Amylyx Pharmaceuticals, a US-based pharmaceutical company, has a high-risk ESG score of 33.8. Specializing in developing innovative therapies for amyotrophic lateral sclerosis and other neurodegenerative diseases, Amylyx focuses solely on research and development in the field of neurodegenerative disorders.